Full-Time

Warehouse Manager

Posted on 10/5/2025

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

Sunnyvale, CA, USA

In Person

Category
Operations & Logistics (2)
,
Required Skills
SAP Products
Requirements
  • Minimum of 14+ years’ experience in Manufacturing operations, preferably in large capital equipment or medical device industry
  • Proficient in the use of personal computers and SAP to perform daily work
  • Familiar with the Microsoft Office suite of programs and MRP systems
  • Proven track record of being an effective Supervisor in a fast-paced manufacturing company, managing the warehouse operations
  • Demonstrated knowledge of Kanban systems, kitting, and other Lean material flow practices
  • Demonstrates concern for precision and thoroughness
  • Proven ability to consistently lead a team to achieve stretch goals and objectives
  • Ability to provide positive direction by encouraging peers to commit to high quality and performance standards
  • Ability to handle multiple tasks and projects successfully
  • Superb communication skills, including written and verbal instruction
  • In-depth knowledge of inventory control systems and processes and root cause analysis
  • Expert knowledge of safety requirements and material handling equipment operation
  • Ability to be flexible in job duties as new facility ramps up into full production
Responsibilities
  • Ensure appropriate staffing levels of warehouse personnel to support ISI business requirements, follows ISI handling procedures, meets high-quality standards, production schedules, operations dept goals, and productivity requirements
  • Maintain documented procedures to define Receiving, Material Movement and Storage, Kitting, and Shipping roles and responsibilities
  • Maintain data compliant with SOX and regulatory controls, including records for timeliness and accuracy of Inventory, Receiving, and Shipping
  • Analyze and correct issues related to Raw Materials and NPI storage quantities and shipped material
  • Optimize operational efficiencies through the application of Lean practices
  • Capacity management and analysis of workloads Identification and elimination of waste in all Warehouse operations
  • Ensure supplier community activities that support internal flow improvements
  • Drive initiatives with cross functional departments such as Planning, Purchasing and Manufacturing on projects that impact warehouse efficiency and productivity
  • Ensure adherence to warehouse metrics. Drive newer productivity metrics
  • Provide vision and direction to the workgroup and drive training to Lean Material flow practices
  • Ensure optimal inventory levels of commodities are maintained to meet production requirements
  • Ensure that company procedures, including SOX and FDA requirements, are understood and adhered to
  • Responsible for managing employee training record completion and status Evaluate and provide annual performance feedback to direct reports and interim counseling to ensure performance criteria are met
  • Implement Short-Term Problem Containment and Long-Term Corrective Action for Shortages and Missed Shipments
  • Drive continuous improvement of current systems and processes and work closely with production planning and management to optimize the value stream opportunities
  • Responsible and accountable for Cycle Counts of required locations per published schedules
  • Performance to Budget Interface with and support: manufacturing, quality control, finance, planning, field service, and order management
Desired Qualifications
  • Other Studies: Lean Manufacturing or Black belt Certification (preferred)
  • Minimum 5-7 + years of experience in the medical industry (preferred)

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Simplify Jobs

Simplify's Take

What believers are saying

  • Bariatric surgery market expansion as da Vinci outperforms GLP-1 drugs for sustained weight loss.
  • Ion bronchoscopy system procedures grew 39% YoY with 1,041 installed units capturing lung cancer detection.
  • Less than 5% of eligible surgeries globally performed robotically indicates substantial international adoption runway.

What critics are saying

  • FDA Class II recalls of instruments with fraying cables disrupt 86% of Q1 recurring revenue.
  • FDA safety communication on curved tip staplers halts hospital use, eroding surgeon confidence in reliability.
  • EU MDR recertification deadline December 2028 halts 25% European sales during redesign and testing.

What makes Intuitive Surgical unique

  • 70-80% market share in soft-tissue robotics with 11,395 installed da Vinci systems globally.
  • 85% recurring revenue from instruments, accessories, and service contracts provides predictable cash flow.
  • da Vinci 5 platform expands into cardiac surgery and complex procedures previously requiring open surgery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 7th, 2026
Intuitive Surgical emerges as dark horse in anti-obesity market as surgery outperforms GLP-1 drugs

Intuitive Surgical could emerge as a dark horse in the anti-obesity market as bariatric surgery proves more effective than GLP-1 drugs for long-term weight loss. A recent study of over 50,000 patients found surgery patients lost an average of 58 pounds after two years, compared to just 12 pounds for those using GLP-1 medications. The study also showed surgery delivers more sustainable results. Gastric bypass patients maintain around 52% of their excess weight loss after 10 years, whilst GLP-1 users often regain all lost weight after stopping treatment. Intuitive's da Vinci surgical system offers minimally invasive bariatric surgery options. The company generated $10.1 billion in revenue last year, up from $8.4 billion, with profit margins around 28%. Despite shares falling over 20% this year, the company's position in surgical innovation makes it a compelling long-term investment.

Yahoo Finance
Mar 29th, 2026
Intuitive Surgical shares drop 19% YTD, but analysts see 15% upside potential

Intuitive Surgical has experienced recent share price weakness, declining 3% in one day with negative returns over the past week, month and three months. The stock currently trades at $452.66, down 10.1% over one month and 19.45% year-to-date, though three-year total shareholder returns remain strong at 77.19%. The medical technology company reports annual revenue of $10.1 billion and net income of $2.9 billion, maintaining a dominant position in minimally invasive surgical technology. According to one valuation analysis, Intuitive Surgical's fair value sits at $532.46, suggesting the stock is undervalued by approximately 15% at current levels. The analysis projects 12% annual revenue growth over the next five years, supported by recurring revenues from spare parts and software licences, with profit margins expected to reach 30% from the current 28.6%.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical shares up 23% after Jim Cramer's buy recommendation

Intuitive Surgical shares rose 23% following Jim Cramer's recommendation on CNBC's Squawk on the Street in June 2025, where he urged investors to "just go buy ISRG". The medical robotics company experienced a 27% surge in October after reporting third-quarter earnings that beat analyst estimates. Revenue reached $2.51 billion against expectations of $2.40 billion, whilst adjusted earnings per share hit $2.40 versus the predicted $1.98. However, the stock declined 2.7% in January 2026 after Intuitive Surgical released preliminary fourth-quarter results, citing concerns that Medicaid funding cuts and competing products could slow growth of its robotic surgical systems. Despite the recent setback, shares remain up significantly since Cramer's initial endorsement, though they're down 7.8% over the past year.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical faces tariff headwinds and rising competition despite 19% revenue growth to $2.87B

Intuitive Surgical faces headwinds from tariffs and increased competition in the robotic-assisted surgery market, yet its fundamentals remain strong. The medical device company reported fourth-quarter revenue growth of 19% to $2.87 billion, whilst adjusted earnings per share rose 14.5% to $2.53. Procedures using its da Vinci surgical system increased 17%, with the installed base growing 12% to 11,106 units. However, the stock trades at 47.6 times forward earnings, compared to the healthcare sector average of 17.1. New competition is emerging, with Medtronic's Hugo system recently cleared and Johnson & Johnson expected to launch its own device soon. Despite these challenges, Intuitive Surgical maintains advantages through switching costs and extensive real-world data, whilst the underpenetrated robotic-assisted surgery market offers long-term growth potential.

Yahoo Finance
Mar 24th, 2026
ISRG maintains 37% operating margins in Q4 despite 95 bps tariff drag

Intuitive Surgical maintained a 37% operating margin in Q4 despite tariffs creating a 95 basis point drag, alongside higher facility costs and unfavourable product mix from newer platforms like da Vinci 5 and Ion. The company offset these pressures through product cost reductions, component savings and manufacturing efficiencies. Procedure growth of 18% in Q4 and recurring revenue now comprising 81% of total revenues provided operating leverage. Management's 2026 gross margin guidance of 67-68% suggests continued stability, even as tariff headwinds are expected to increase to roughly 1.2% of revenues. Meanwhile, Boston Scientific expanded adjusted operating margins by 100 basis points to 28% in 2025, though tariffs will offset favourable product mix in 2026. The company expects 50-75 basis points operating margin expansion in 2026 through scale efficiencies and supply-chain optimisation.

INACTIVE